Address: 1Congenital Heart Center University of Florida, College of Medicine, Gainesville, FL, USA, 2Duke University Medical Center, Durham, NC, USA, 3Department of Medical Genetics, University of Ferrara, Ferrara, Italy, 4Department of Neurology, University of Munich, Munich, Germany, 5Erasmus Medical Center, Sophia,, Rotterdam, Netherlands and 6Genzyme Corporation, Cambridge, MA, USA * Corres...

We present a case of glycogen storage disease type II (Pompe's disease) with the classical clinical presentation and characteristic electrocardiographic changes of this disorder. An acid maltase (EC 3.2.1.20) determination in the peripheral leukocytes revealed normal activity; however, acid maltase activity was completely absent in a pre-mortem skeletal muscle biopsy. Post-mortem studies showed...

Pompe's disease (acid maltase deficiency, glycogen storage disease type II) is an autosomal recessive disorder caused by a deficiency of lysosomal acid α-1,4-glucosidase, resulting in excessive accumulation of glycogen in the lysosomes and cytoplasm of all tissues, most notably in skeletal muscles. We present a case of adult-onset Pompe's disease with progressive proximal muscles weakness over ...

Pompe disease (glycogen storage disease type II) is a glycogen storage disease caused by a deficiency of the lysosomal enzyme, acid maltase/acid alpha-1,4 glucosidase (GAA). Deficiency of the enzyme leads primarily to intra-lysosomal glycogen accumulation, primarily in cardiac and skeletal muscles, due to the inability of converting glycogen into glucose. Enzyme replacement therapy (ERT) has be...

Pompe disease (glycogen storage disease type II, acid maltase deficiency) is a progressive metabolic myopathy caused by deficiency of the lysosomal enzyme acid alpha-glucosidase. This leads to an accumulation of glycogen in various tissues of the body, most notably in skeletal muscle. The disease has an autosomal recessive inheritance with a predicted frequency of 1 :40.000. Pompe disease is a ...

Glycogen storage disease type II (GSDII)/Pompe disease is an autosomal recessive multi-system disorder due to a deficiency of the glycogen-degrading lysosomal enzyme, acid alpha-glucosidase (GAA). Without adequate levels of GAA, there is a progressive accumulation of glycogen inside the lysosome, resulting in lysosomal expansion in many tissues, although the major clinical manifestations are se...

In classic infantile-onset Pompe disease (IOPD), symptoms start early in life, and there is a fatal outcome if the disease remains untreated.1 Enzyme replacement therapy (ERT) with recombinant human GAA remains the single treatment favouring a prolonged life expectancy.2–4 To our knowledge, there have been no studies investigating the role of an early and intensive global rehabilitation program...

The angiographic and haemodynamic findings in 2 cases of Pompe's disease (glycogenosis type II) indicated an abnormal trabecular pattern, not previously reported, on the left ventricular angiogram of both patients. This feature may be helpful in distinguishing Pompe's disease from other forms of myocardial abnormality.

BACKGROUND Neonatal screening for Pompe disease has been introduced in Taiwan and a few U.S. states, while other jurisdictions including some European countries are piloting or considering this screening. First-tier screening flags both classic infantile and late-onset Pompe disease, which challenges current screening criteria. Previously, advocacy groups have sometimes supported expanded neona...